IL254576A0 - Methods and preparations for intravenous administration of fumarates for the treatment of neurological diseases - Google Patents
Methods and preparations for intravenous administration of fumarates for the treatment of neurological diseasesInfo
- Publication number
- IL254576A0 IL254576A0 IL254576A IL25457617A IL254576A0 IL 254576 A0 IL254576 A0 IL 254576A0 IL 254576 A IL254576 A IL 254576A IL 25457617 A IL25457617 A IL 25457617A IL 254576 A0 IL254576 A0 IL 254576A0
- Authority
- IL
- Israel
- Prior art keywords
- fumarates
- compositions
- treatment
- methods
- intravenous administration
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 title 1
- 238000001990 intravenous administration Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562136431P | 2015-03-20 | 2015-03-20 | |
| PCT/US2016/023021 WO2016153957A2 (en) | 2015-03-20 | 2016-03-18 | Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL254576A0 true IL254576A0 (en) | 2017-11-30 |
Family
ID=55702079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL254576A IL254576A0 (en) | 2015-03-20 | 2017-09-18 | Methods and preparations for intravenous administration of fumarates for the treatment of neurological diseases |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20180289655A1 (https=) |
| EP (1) | EP3270895A2 (https=) |
| JP (1) | JP2018508559A (https=) |
| KR (1) | KR20170138437A (https=) |
| CN (1) | CN107666905A (https=) |
| AR (1) | AR104029A1 (https=) |
| AU (1) | AU2016235743A1 (https=) |
| CA (1) | CA2979544A1 (https=) |
| EA (1) | EA201792076A1 (https=) |
| HK (1) | HK1244680A1 (https=) |
| IL (1) | IL254576A0 (https=) |
| MA (1) | MA41785A (https=) |
| MX (1) | MX2017012239A (https=) |
| TW (1) | TW201642847A (https=) |
| WO (1) | WO2016153957A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202116297A (zh) * | 2019-07-03 | 2021-05-01 | 西班牙商布爾奴爾法碼有限公司 | 組合療法之方法、組成物與套組 |
| TW202131914A (zh) | 2019-10-30 | 2021-09-01 | 西班牙商布爾奴爾法碼有限公司 | 用於神經疾病或病狀的治療之新治療方案 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| SI1663197T1 (sl) * | 2003-09-09 | 2008-06-30 | Biogen Idec Internat Gmbh | Uporaba derivatov fumarne kisline za zdravljenje sräśne insuficience in astme |
| CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| LT2801354T (lt) * | 2004-10-08 | 2017-06-26 | Forward Pharma A/S | Kontroliuojamo atpalaidavimo farmacinės kompozicijos, apimančios fumaro rūgšties esterį |
| WO2007042035A2 (en) | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| US20080089861A1 (en) | 2006-07-10 | 2008-04-17 | Went Gregory T | Combination therapy for treatment of demyelinating conditions |
| SI2139467T1 (sl) * | 2007-02-08 | 2017-01-31 | Biogen Ma Inc. | Zaščita živčevja pri demielinizacijskih obolenjih |
| EP2680006A1 (en) * | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Treatment for Amyotrophic Lateral Sclerosis |
| EP2307456B1 (en) | 2008-06-27 | 2014-10-15 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| HRP20140640T1 (hr) | 2008-08-19 | 2014-11-21 | Xenoport, Inc. | Prolijekovi monometil estera fumarne kiseline, farmaceutski sastavi iz toga i postupci njihove uporabe |
| US20120165404A1 (en) | 2009-04-29 | 2012-06-28 | Biogen Idec Ma Inc. | Treatment of neurodegeneration and neuroinflammation |
| HUE025878T2 (en) | 2010-02-12 | 2016-05-30 | Biogen Ma Inc | Neuroprotection in demyelinating diseases |
| JP5072128B2 (ja) * | 2011-03-31 | 2012-11-14 | 株式会社ワコール | カップ部を有する衣類 |
| WO2013022882A1 (en) | 2011-08-08 | 2013-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | Combination therapy for treatment of inflammatory demyelinating disease |
| EP2791181A4 (en) * | 2011-12-16 | 2015-08-05 | Biogen Ma Inc | SILICONE-CONTAINING FUMIC ACID ESTERS |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| NZ627980A (en) * | 2012-02-07 | 2016-12-23 | Biogen Ma Inc | Pharmaceutical compositions containing dimethyl fumarate |
| WO2014031901A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of use for monomethyl fumarate and prodrugs thereof |
| US9868690B2 (en) | 2012-12-21 | 2018-01-16 | Ratiopharm Gmbh | Prodrugs of monomethyl fumarate (MMF) |
| AR094277A1 (es) * | 2012-12-21 | 2015-07-22 | Biogen Idec Inc | Derivados de fumarato sustituidos con deuterio |
| DK2943189T3 (da) | 2013-01-08 | 2021-04-06 | Pathologica Llc | Mitoguazon til behandling af progressiv multipel sklerose |
| WO2014138298A1 (en) | 2013-03-05 | 2014-09-12 | University Of Chicago | Treatment of demyelinating disorders |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| US20150079180A1 (en) * | 2013-09-18 | 2015-03-19 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
| CN103768045B (zh) * | 2013-10-30 | 2015-10-07 | 苏州大学附属第一医院 | 富马酸二甲酯在制备治疗蛛网膜下腔出血后早期脑损伤药物的应用 |
| WO2016074684A1 (en) * | 2014-11-11 | 2016-05-19 | Syddansk Universitet | Fumaric acid derivatives for medical use |
-
2016
- 2016-03-17 MA MA041785A patent/MA41785A/fr unknown
- 2016-03-18 US US15/559,265 patent/US20180289655A1/en not_active Abandoned
- 2016-03-18 JP JP2017549232A patent/JP2018508559A/ja not_active Withdrawn
- 2016-03-18 AR ARP160100749A patent/AR104029A1/es unknown
- 2016-03-18 WO PCT/US2016/023021 patent/WO2016153957A2/en not_active Ceased
- 2016-03-18 CA CA2979544A patent/CA2979544A1/en not_active Abandoned
- 2016-03-18 EA EA201792076A patent/EA201792076A1/ru unknown
- 2016-03-18 AU AU2016235743A patent/AU2016235743A1/en not_active Withdrawn
- 2016-03-18 CN CN201680028617.1A patent/CN107666905A/zh not_active Withdrawn
- 2016-03-18 MX MX2017012239A patent/MX2017012239A/es unknown
- 2016-03-18 TW TW105108578A patent/TW201642847A/zh unknown
- 2016-03-18 HK HK18104073.2A patent/HK1244680A1/zh unknown
- 2016-03-18 EP EP16715662.9A patent/EP3270895A2/en not_active Withdrawn
- 2016-03-18 KR KR1020177029928A patent/KR20170138437A/ko not_active Abandoned
-
2017
- 2017-09-18 IL IL254576A patent/IL254576A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107666905A (zh) | 2018-02-06 |
| KR20170138437A (ko) | 2017-12-15 |
| US20180289655A1 (en) | 2018-10-11 |
| EP3270895A2 (en) | 2018-01-24 |
| WO2016153957A2 (en) | 2016-09-29 |
| EA201792076A1 (ru) | 2018-04-30 |
| HK1244680A1 (zh) | 2018-08-17 |
| AR104029A1 (es) | 2017-06-21 |
| MX2017012239A (es) | 2018-06-27 |
| TW201642847A (zh) | 2016-12-16 |
| WO2016153957A3 (en) | 2016-11-10 |
| JP2018508559A (ja) | 2018-03-29 |
| MA41785A (fr) | 2018-01-23 |
| CA2979544A1 (en) | 2016-09-29 |
| AU2016235743A1 (en) | 2017-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298689B1 (en) | Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions | |
| ZA201901279B (en) | Compositions and methods for treatment of neurological disorders | |
| IL274702A (en) | Compounds and Methods for Neurological Diseases | |
| HUE065662T2 (hu) | Készítmények és eljárások betegségek kezelésére | |
| PT3122878T (pt) | Terapia de arnm para o tratamento de doenças oculares | |
| ZA201903003B (en) | Treatment of neurological diseases | |
| EP3268007A4 (en) | Compositions and therapeutic methods for the treatment of complement-associated diseases | |
| IL258032A (en) | Compounds and preparations for the treatment of ocular disorders | |
| ZA202006234B (en) | Compositions and methods for the treatment of neurological diseases | |
| IL249439A0 (en) | A compound and method for the treatment of neurological diseases and brain injury | |
| IL320533A (en) | Methods and compositions for treating disorders and diseases involving RDH12 | |
| GB201412578D0 (en) | Treatment of neurological diseases | |
| MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
| IL254576A0 (en) | Methods and preparations for intravenous administration of fumarates for the treatment of neurological diseases | |
| IL257689B (en) | Pharmaceutical preparations and methods for treating diseases related to lack of oxygen | |
| SG11201706952VA (en) | Compositions and methods for the treatment of epilepsy and neurological disorders | |
| GB201603510D0 (en) | Compositions for use in the treatment of neurological disease | |
| EP3129054A4 (en) | Methods and compositions for the treatment of ocular diseases and disorders | |
| HK40009011A (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| IL254140A0 (en) | Preparations and combinations for use in the treatment of angiogenic diseases and disorders | |
| EP3247396A4 (en) | Methods and compositions for the treatment of diseases and disorders | |
| GB201706662D0 (en) | Treatment of neurological diseases | |
| GB201516303D0 (en) | Compositions and methods relating to the treatment of diseases | |
| AU2016901682A0 (en) | Compositions for the Treatment of Diseases and Conditions | |
| HUP1300454A2 (hu) | Daganatos betegségek gyógyítására és megelõzésére alkalmas gyógyászati készítmények, és eljárás azok elõállítására |